The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.

Martinetti A, Ferrari L, Celio L, Mariani L, Miceli R, Zilembo N, Di Bartolomeo M, Toffolatti L, Pozzi P, Seregni E, Bombardieri E, Bajetta E

The Journal of steroid biochemistry and molecular biology1 Dec 2000Cited by 3 (Europe PMC)

PMID11179910DOI10.1016/s0960-0760(00)00138-2PepBankPUB-11179910

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, PICP increased during triptorelin alone.
In plain wordsIn breast cancer patients, PICP increased during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePICP
Study
n = 10
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
serum PICP and PINP levels increased significantly over time (P=0.0065 and 0.0197 in arm A and B, respectively); no change in ICTP levels was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
Report a problemFND-1117991001
02HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, PINP increased during triptorelin alone.
In plain wordsIn breast cancer patients, PINP increased during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePINP
Study
n = 10
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
serum PICP and PINP levels increased significantly over time (P=0.0065 and 0.0197 in arm A and B, respectively); no change in ICTP levels was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
Report a problemFND-1117991002
03HumanRandomized controlled trialEfficacy outcome
In breast cancer patients, ICTP did not change during triptorelin alone.
In plain wordsIn breast cancer patients, ICTP did not change during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeICTP
Study
n = 10
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
serum PICP and PINP levels increased significantly over time (P=0.0065 and 0.0197 in arm A and B, respectively); no change in ICTP levels was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
Report a problemFND-1117991003
04HumanRandomized controlled trialEfficacy outcome
In breast cancer patients, IGF-I increased significantly during triptorelin alone.
In plain wordsIn breast cancer patients, IGF-I increased during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseIGF-I
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
A rise in IGF-I and IGFBP-3 levels was seen in each treatment group, but only the increase in IGF-I was significant (P=0.0138, always).
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
Report a problemFND-1117991004
05HumanRandomized controlled trialEfficacy outcome
In breast cancer patients, IGFBP-3 rose nonsignificantly during triptorelin alone.
In plain wordsIn breast cancer patients, the IGFBP-3 rise during triptorelin alone was not significant.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeIGFBP-3
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
A rise in IGF-I and IGFBP-3 levels was seen in each treatment group, but only the increase in IGF-I was significant (P=0.0138, always).
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
Report a problemFND-1117991005
06HumanRandomized controlled trialEfficacy outcome
In breast cancer patients, triptorelin alone did not significantly affect serum IL-6.
In plain wordsIn breast cancer patients, triptorelin alone did not significantly change IL-6.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeIL-6
Study
n = 10
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Neither treatment modalities significantly affected serum IL-6 levels over time.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
Report a problemFND-1117991006

Studies that did not test the peptide alone9

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In breast cancer patients, PICP increased during triptorelin plus formestane.
In plain wordsIn breast cancer patients, PICP increased during triptorelin plus formestane.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePICP
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
serum PICP and PINP levels increased significantly over time (P=0.0065 and 0.0197 in arm A and B, respectively); no change in ICTP levels was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991007
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In breast cancer patients, PINP increased during triptorelin plus formestane.
In plain wordsIn breast cancer patients, PINP increased during triptorelin plus formestane.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePINP
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
serum PICP and PINP levels increased significantly over time (P=0.0065 and 0.0197 in arm A and B, respectively); no change in ICTP levels was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991008
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In breast cancer patients, ICTP did not change during triptorelin plus formestane.
In plain wordsIn breast cancer patients, ICTP did not change during triptorelin plus formestane.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeICTP
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
serum PICP and PINP levels increased significantly over time (P=0.0065 and 0.0197 in arm A and B, respectively); no change in ICTP levels was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991009
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In breast cancer patients, IGF-I increased significantly during triptorelin plus formestane.
In plain wordsIn breast cancer patients, IGF-I increased during triptorelin plus formestane.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseIGF-I
Study
n = 11
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
A rise in IGF-I and IGFBP-3 levels was seen in each treatment group, but only the increase in IGF-I was significant (P=0.0138, always).
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991010
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In breast cancer patients, IGFBP-3 rose nonsignificantly during triptorelin plus formestane.
In plain wordsIn breast cancer patients, the IGFBP-3 rise during triptorelin plus formestane was not significant.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeIGFBP-3
Study
n = 11
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
A rise in IGF-I and IGFBP-3 levels was seen in each treatment group, but only the increase in IGF-I was significant (P=0.0138, always).
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991011
12HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In breast cancer patients, triptorelin plus formestane did not significantly affect serum IL-6.
In plain wordsIn breast cancer patients, triptorelin plus formestane did not significantly change IL-6.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeIL-6
Study
n = 11
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Neither treatment modalities significantly affected serum IL-6 levels over time.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991012
13HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In the triptorelin-based treatment cohort, bone turnover markers correlated inversely with serum oestrogens.
In plain wordsIn the triptorelin-based treatment cohort, higher bone turnover markers were linked to lower oestrogens.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone turnover marker association with oestrogens
Study
n = 21
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The on-treatment levels of the bone turnover markers and IGF-system components were inversely correlated with serum oestrogens.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991013
14HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In the triptorelin-based treatment cohort, IGF-system components correlated inversely with serum oestrogens.
In plain wordsIn the triptorelin-based treatment cohort, higher IGF-system components were linked to lower oestrogens.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseIGF-system association with oestrogens
Study
n = 21
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The on-treatment levels of the bone turnover markers and IGF-system components were inversely correlated with serum oestrogens.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991014
15HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In the triptorelin-based treatment cohort, assessed biomarker behavior did not differ by skeletal metastasis status.
In plain wordsIn the triptorelin-based treatment cohort, biomarker behavior did not differ between patients with and without skeletal metastases.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBiomarker behavior by skeletal metastasis status
Study
n = 21
Comparator
Patients without skeletal metastases
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
No difference in the behaviour of any of the assessed biomarkers was observed between patients with or without skeletal metastases.
2 context sentences(design, population, supporting numbers)
Summary · context
twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n=10, arm A) or in combination with formestane fortnightly (n=11, arm B).
Summary · context
Blood samples were collected over a 3-month period.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1117991015

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.